Searched for
LINAGLIPTIN TABLETS
Fresh tailwinds emerge as government comes in again with intent: 7 pharma stocks with upside potential of up to 36%Budget 2026 underlines the government’s intent – in terms of the sectors it will focus on. Now, it is not all of a sudden that the governme...- Zydus Lifesciences shares in focus after US FDA nods for diabetes and blood pressure drugsZydus Lifesciences is set to be in focus after it received tentative approval from the United States Food and Drug Administration for Empag...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of more than 25%The markets have a big element of probability. The way things have panned out in the past few weeks, it is very likely that the bulls will ...
- New affordable diabetes drug Empagliflozin launched in IndiaSeveral domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices follo...
- Nifty healthcare index stocks; Staying bullish on select pharma and hospitalsWhile they clubbed together, the operating matrix of a pharma company making drugs and hospital and a diagnostic company are very different...
- Nifty healthcare index stocks analysts suggest buying have potential upside of more than 19%Except for a pocket in which demand for covid drugs led to sharp surge in pharma stocks, the pharma sector had been under pressure for a lo...
- Pricing authority caps rates of key diabetes drugsIndia’s drug pricing authority has fixed prices of two key anti diabetes drugs-Sitagliptin-Metformin combination and Linagliptin-metformin ...
- Zydus Cadila gets tentative nod from USFDA to market diabetes drugThe company said the newly approved medication will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
- Zydus Cadila gets USFDA nod for generic drugsThe company has received final approval from the US Food and Drug Administration (USFDA) for the medication in 300 mg strength, Zydus Cadil...
- Alembic Pharmaceuticals gets USFDA's tentative approval for type 2 diabetes drugThe tentatively approved abbreviated new drug application (ANDA) is therapeutically equivalent to the reference listed drug product Glyxamb...
- India rejects compulsory license application of Lee Pharma against AstraZeneca’s SaxagliptinThe Indian Patent Office has rejected the application of Lee Pharma for a compulsory license on AstraZeneca’s anti-diabetes drug saxaglipti...
- Boehringer Ingelheim, Eli Lilly launch Linagliptin tabletsBoehringer Ingelheim India and Eli Lilly and Company India (Lilly) today said they have launched Linagliptin tablets used for treating diab...
Load More
